Patients and science are at the center<br />of everything we do

Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial